ArticleFrontiers in oncology2020

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.

Yao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.